TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2096405
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine 48 mg/70 kg
Study: 2096405
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine 96 mg/70 kg
Study: 282906
Drug: Cyclic administration
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic administration of arabinosyl cytosine and vincristine plus prednisone
Study: 282906
Drug: Cyclic administration
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic administration of arabinosyl cytosine plus thioguanine plus daunomycin
Study: 21681619
Drug: Bone marrow-derived
Normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived stem cell (BMC) therapy
Study: 18496303
Drug: Ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.25 mg/kg at induction with morphine
Study: 18496303
Drug: Morphine only
Normalized name: Morphine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine only (Control)
Study: 16275797
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy (amantadine hydrochloride or oseltamivir phosphate)
Study: 7486094
Drug: Ketorolac 1
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1 mg/kg IV
Study: 31085219
Drug: CytoSorb hemoadsorption
Normalized name: DRESSING,CUTISORB ULTRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CytoSorb hemoadsorption therapy
Study: 29057795
Drug: Piceatannol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piceatannol (20 mg/day)
Study: 27137718
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg opicapone
Study: 16283320
Drug: 880 IU
Normalized name: bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 880 IU vitamin D plus 1 g calcium carbonate
Study: 12043851
Drug: Budesonide Turbuhaler,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide Turbuhaler, 100 microg twice‐daily (b.i.d.)
Study: 7789372
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy for acute myocardial infarction in patients aged ≤ 40 years
Study: 7789372
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy for acute myocardial infarction in patients aged > 40 years
Study: 2189246
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mefloquine + sulfadoxine + pyrimethamine (MSP)
Study: 2189246
Drug: Lowest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest dose of MSP (10 mg/kg M + 20 mg/kg S + 1.0 mg/kg P)
Study: 494166
Drug: Intermittent sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent sequential calf compression
Study: 29075107
Drug: Aerosolized hyaluronan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized hyaluronan (HA), 150 kDa, administered for 2 weeks
Study: 23463769
Drug: Bear bile
Normalized name: bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bear bile capsule and Huangqi granule daily (Group B)
Study: 23463769
Drug: Massaging the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massaging the children's parotid region and melting vitamin C in their mouth daily (Group A)
Study: 23463769
Drug: Massages and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massages and vitamin C as prescribed in Group A, and traditional Chinese medicine as prescribed in Group B (Group C)
Study: 9638315
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pantoprazole daily
Study: 15087692
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg esomeprazole daily
Study: 11304654
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide (Al(OH)3) with citrate/citric acid solution (CCA) concurrently with meals
Study: 11304654
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide (Al(OH)3) with citrate/citric acid solution (CCA) 2 hours after meals
Study: 9484361
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) treatment (0.4 g/kg/day for 5 days, then 0.4 g/kg every 2 months for 2 years)
Study: 9484361
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) treatment and Placebo
Study: 8306818
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g) administered 30 min preoperatively
Study: 8306818
Drug: Mezlocillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (2 g) and oxacillin (1 g) administered over 24 h (3 injections)
Study: 30993478
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Trauma and Self-Care (CBT-TSC)
Study: 27234569
Drug: Acceptance Commitment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance Commitment Therapy-based group intervention delivered via videoconferencing in six 90 min group sessions
Study: 20939985
Drug: Normal control
Normalized name: Precision, Normal Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal control group (no treatment)
Study: 20939985
Drug: Normal mice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal mice (no treatment)
Study: 12432437
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa administered intravenously (IV)
Study: 12432437
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa administered subcutaneously (SC)
Study: 2176097
Drug: 1% lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine, 3 mg/kg, diluted with physiological saline solution (pH = 6.63 +/‐ 0.05)
Study: 2176097
Drug: 1% lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine, 3 mg/kg, diluted with 1.4% sodium bicarbonate (pH = 7.34 +/‐ 0.05)
Study: 20182846
Drug: Manganese chloride
Normalized name: Manganese Chloride
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manganese chloride tetrahydrate (Bothdel Oral Solution 10) (MCT)
Study: 20182846
Drug: No agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No agent
Study: 16122538
Drug: Dual-focus schema
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-focus schema therapy (DFST)
Study: 18202666
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day for 12 weeks
Study: 13130405
Drug: Intranasal mupirocin;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mupirocin; specific dosage and duration not mentioned.
Study: 10836915
Drug: Trimethoprim-sulfamethoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (160 mg or 800 mg)
Study: 1505371
Drug: Amoxicillin/clavulanate (500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (500/125 mg three times daily)
Study: 28654918
Drug: tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 5 mg b.i.d.
Study: 28654918
Drug: tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 10 mg b.i.d.
Study: 19951447
Drug: Piperacillin/tazobactam (recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (recommended dose)
Study: 17535624
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate 200 mg TDS for 2 weeks pre-operatively
Study: 20124051
Drug: No iron
Normalized name: No Iron Multivitamin with Minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: No iron therapy
Study: 8035916
Drug: IV penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV penicillin G (3 g q 6 h)
Study: 8035916
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline (200 mg q 24 h)
Study: 28422462
Drug: Oral-B 7000
Normalized name: POLYETHYLENE GLYCOL 7000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B 7000 with CrossAction brush head (OCA)
Study: 26463446
Drug: Standard corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard corticosteroid therapy (SCT) and hyperbaric oxygen (HBO) therapy without rTMS.
Study: 23628132
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU vitamin D3 weekly for 8 weeks
Study: 23628132
Drug: Multivitamin supplement
Normalized name: Vi-Daily Multivitamin Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplement containing 400 IU vitamin D3/d
Study: 11720431
Drug: Paclitaxel formulated
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel formulated in Cremophor EL 15 ml m(‐2)
Study: 3295122
Drug: Methylprednisolone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (500 mg)
Study: 21206418
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid for 14 days
Study: 21206418
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg bid and amoxicillin 1 g bid for 7 days, followed by metronidazole 500 mg bid, tetracycline 500 mg qid, and lansoprazole 30 mg bid for an additional 7 days
Study: 17460497
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (12.5 mg zinc sulfate tablet daily for about 6 months)
Study: 11956122
Drug: Moxonidine SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine SR 1.5 mg BID
Study: 11956122
Drug: Moxonidine SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine SR (0.3, 0.6, 0.9, 1.2, or 1.5 mg BID)
Study: 378733
Drug: Phenylpropanolamine 50
Normalized name: phenylpropanolamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine 50 mg
Study: 378733
Drug: Phenylpropanolamine 100
Normalized name: guaifenesin-phenylpropanolamine 100 mg-20 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine 100 mg
Study: 31693078
Drug: 1 month
Normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 month of dual antiplatelet therapy (DAPT) followed by 23 months of ticagrelor monotherapy
Study: 31693078
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of DAPT followed by 12 months of aspirin monotherapy
Study: 28577272
Drug: ADV6209 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV6209 (15 mg, oral)
Study: 28577272
Drug: Midazolam hydrochloride
Normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam hydrochloride intravenous solution (5 mg, i.v.)
Study: 25813411
Drug: Thrice-daily (TID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily (TID) U‐500R insulin
Study: 25813411
Drug: Twice-daily (BID)
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily (BID) U‐500R insulin
Study: 23816977
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 20% hydroxypropyl‐β‐cyclodextrin (2‐HPβCD) in a polyethylene glycol (PEG) formulation, applied twice daily for 6 months.
Study: 23816977
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control (PEG formulation without 2‐HPβCD), applied twice daily for 6 months.
Study: 16492824
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg sublingually 2 hours before surgery
Study: 16492824
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg sublingually 10 minutes after surgery (Control)
Study: 15075512
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 200/100 mg
Study: 15075512
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 400/100 mg
Study: 15075512
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 400/200 mg
Study: 15075512
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) open-label 400/100 mg
Study: 9007492
Drug: Budesonide (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (inhaled group, 100 micrograms qds) for 10 days
Study: 3115153
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg . kg‐1)
Study: 3115153
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with Alfentanil (2 mg . kg‐1 propofol with 4 micrograms . kg‐1 alfentanil)
Study: 3115153
Drug: Ketamine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine with Midazolam (0.5 mg . kg‐1 ketamine with 0.25 mg . kg‐1 midazolam)
Study: 3115153
Drug: Ketamine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine with Midazolam (1 mg . kg‐1 ketamine with 0.1 mg . kg‐1 midazolam)
Study: 29685017
Drug: Posterior hemivertebra
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior hemivertebra resection in combination with screw rod internal fixation
Study: 27010115
Drug: PPS 100
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPS 100 mg thrice daily
Study: 27010115
Drug: PPS 100
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPS 100 mg once daily and placebo twice daily
Study: 27010115
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin B complex tablet) thrice daily
Study: 23874094
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg daily for 7 days
Study: 10870071
Drug: Cefixime (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (8 mg/kg/day orally for 4 days) after 3 days of intravenous ceftriaxone (100 mg/kg/day) and amikacin (15 mg/kg/day)
Study: 9100553
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (rhGH; mean dose 2.4 IU daily)
Study: 8096959
Drug: halofantrine (72
Approvals — FDA: no, EMA: no, PMDA: no
Description: halofantrine (72 mg/kg)
Study: 8096959
Drug: halofantrine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: halofantrine (24 mg/kg, 3 doses)
Study: 8096959
Drug: mefloquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: mefloquine (25 mg/kg)
Study: 3589701
Drug: continued interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: continued interferon therapy
Study: 30268528
Drug: Ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2 mg/kg/h)
Study: 17135784
Drug: Propiverine hydrochloride
Normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine hydrochloride immediate release (IR) 15 mg twice daily
Study: 17135784
Drug: Propiverine hydrochloride
Normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine hydrochloride extended release (ER) 30 mg once daily
Study: 31162005
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine only
Study: 31162005
Drug: Vaccine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine plus behavior change (cholera vaccine and handwashing plus drinking water chlorination promotion)
Study: 31162005
Drug: Vaccine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine plus behavior change
Study: 31162005
Drug: Vaccine only
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine only
Study: 25753159
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment protocol for gestational diabetes
Study: 25753159
Drug: Regular method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular method of treatment for gestational diabetes
Study: 20660131
Drug: 38 per
Normalized name: caffeine 38 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38 per cent phosphoric acid gel
Study: 20660131
Drug: 9.6 per
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.6 per cent hydrofluoric acid gel
Study: 20660131
Drug: Control with
Normalized name: Azo Bladder Control With Go Less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control with no surface treatment
Study: 9213276
Drug: Thigh-high sequential
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thigh-high sequential pneumatic compression wraps
Study: 8424297
Drug: Combined thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined thoracic epidural anaesthesia/light general anaesthesia with continuous epidural bupivacaine 10 mg.h‐1 and morphine 0.2 mg.h‐1 for 38 h after surgery plus systemic ibuprofen 600 mg x 8 h‐1
Study: 8424297
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia and postoperative analgesia with systemic morphine and ibuprofen 600 mg x 8 h‐1
Study: 3117467
Drug: Nitroglycerin-TTS 5
Normalized name: nitroglycerin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin-TTS 5 mg/24 h
Study: 3117467
Drug: Long-acting nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting nitroglycerin tablets, 10.4 mg daily
Study: 31910658
Drug: DSR solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSR solution (sodium-free 10% dextrose)
Study: 31910658
Drug: Standard PD
Normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PD solution (Dianeal 4.25% dextrose)
Study: 30120404
Drug: DHA-CHO-VE treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-CHO-VE treatment
Study: 27621162
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg controlled release twice a day)
Study: 23944684
Drug: High-caloric food
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-caloric food supplement with high fat content
Study: 23944684
Drug: High-caloric food
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-caloric food supplement with high carbohydrate content
Study: 19082800
Drug: Shengmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengmai injection (SMI)
Study: 12821964
Drug: Intensive diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive diet therapy (6000-7000 kJ/day or 1400-1700 kcal/day) with weekly dietitian contact for 12 weeks
Study: 10364866
Drug: Ketamine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2.5 mg.kg‐1
Study: 8322572
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg.kg‐1
Study: 2222943
Drug: Intravenous captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous captopril
Study: 6301671
Drug: Adriamycin (doxorubicin)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (doxorubicin) 50 mg/m2 IV every three weeks
Study: 6301671
Drug: Adriamycin (doxorubicin)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (doxorubicin) 75 mg/m2 IV every three weeks
Study: 26559482
Drug: Topical imiquimod-cream
Normalized name: Imiquimod Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod-cream followed by intradermal trivalent influenza vaccine (INF-Q-ID)
Study: 26559482
Drug: Topical aqueous-cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous-cream control followed by intradermal trivalent influenza vaccine (INF-C-ID)
Study: 26559482
Drug: Topical aqueous-cream
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous-cream control followed by intramuscular trivalent influenza vaccine (INF-C-IM)
Study: 26559482
Drug: Topical imiquimod-cream
Normalized name: Imiquimod Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod-cream followed by intradermal normal-saline injection (SAL-Q-ID)
Study: 12094862
Drug: 60‐100 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60‐100 mg/day prednisolone equivalent, tapered to 10‐15 mg/day within 6 weeks and maintained for another 4 weeks
Study: 12094862
Drug: Steroid resistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid resistant patients
Study: 9685127
Drug: Dextran 40
Normalized name: Dextran 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 40 infusion for 72 hours after surgery
Study: 9685127
Drug: No dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dextran 40 infusion
Study: 8600180
Drug: Intravenous pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pilocarpine (P)